Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.

ABSTRACT:

Clinical trials registration

NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II).

SUBMITTER: Prabhu VS 

PROVIDER: S-EPMC5848255 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature